前往化源商城

97-29-0 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:15378 靶标:N/A
External ID: TELO_02
Protocol: HCT116 colorectal cancer cells are infected with Ad-hTR-mut and cytotoxicity is assessed 5-days post infection, measured by standard MTT assay. Ad-hTR-mut constructed using the Adeasy system (Agilent) and purified and quantified using Adeno-x purification and rapid titre kits (Clontech). Cells are seeded at 10000 cells per well and infected with 500pfu/cell in 96 well plates (Costar) then incubated for 48h prior to addition of compounds. Compounds were screened at 10uM in duplicate 2 days post-infection and MTT assay performed 3 days later at 5 days post-infection. A negative control adenovirus was included on every plate as a control for non-specific viral toxicity and all wells were expressed relative to untreated cells. Absorbance at 570nm was determined using a Molecular Devices spectramax plus instrument and analysed using SoftMax Pro software. Hits were taken to be compounds giving greater than 2.5-fold increase in absorbance indicating increased cell survival.
Comment: Target cell viability at time of assay was 30-50% after infection with this stock of Ad-hTR-mut. Compounds giving 2.5-fold increase in survival relative to this condition were taken to be hits.
PUBCHEM_CIDAverage fold change at 10uM
28352452.37345151761089
57627322.36991761817046
2737242.3633566237567
4280442.36007795439464
43727212.35604391203318
39815872.35272774293471
57618102.33290828855493
28296062.31292518175006
58661412.30539893051177
29311612.27513175470908
10403702.27281433832202
28142402.26165663543268
63730072.25090778161813
6732342.24926143067941
51908012.2419406617287
28352072.22660017924689
52809602.21063591324776
46559712.19507356532407
1704752.19458458305062
28273432.18358659086153
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: MCF7_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, MCF7 is panel number 5, cell number 1. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
2106OS49SM1.0E-551Breast CancerMCF7BRE88.231101
2106OS49SM1.0E-551Breast CancerMCF7BRE87.1119101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.4371101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.7113101
2106OS49SM1.0E-551Breast CancerMCF7BRE97.2463101
2106OS49SM1.0E-551Breast CancerMCF7BRE90.0129101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.7031101
2106OS49SM1.0E-551Breast CancerMCF7BRE30.8539101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.2896101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.8526101
2106OS49SM1.0E-551Breast CancerMCF7BRE83.1036101
2106OS49SM1.0E-551Breast CancerMCF7BRE84.2194101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.3237101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.6034101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.6643101
2106OS52SM1.0E-551Breast CancerMCF7BRE91.2503101
2106OS52SM1.0E-551Breast CancerMCF7BRE94.8714101
2106OS52SM1.0E-551Breast CancerMCF7BRE93.7372101
2106OS52SM1.0E-551Breast CancerMCF7BRE112.6132101
2106OS52SM1.0E-551Breast CancerMCF7BRE73.375101
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL944269
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2009
Volume: 52
Issue: 4
First Page: 952
Last Page: 963
DOI: 10.1021/jm8008103

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
6.1IC50=6100nM
3.2IC50=3200nM
64.3IC50=64300nM
230.2IC50>230200nMOutside typical range
49.9IC50>49900nM
8IC50=8000nM
49.9IC50>49900nM
6.7IC50=6700nM
12IC50=12000nM
5.5IC50=5500nM
6.6IC50=6600nM
1.4IC50=1400nM
49.9IC50>49900nM
11.4IC50=11400nM
16.4IC50=16400nM
45.7IC50=45700nM
55.3IC50>55300nM
20.7IC50=20700nM
5.8IC50=5800nM
41.2IC50>41200nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:BindingDB 靶标:N/A
External ID: BindingDB_7962_1
Protocol: N/A
Comment: Compounds with any of Ki, IC50, Kd, or EC50 activity value <= 10uM are labeled as "Active".
If multiple measurements are available for a given compound, it is labeled as "Active" if any of the measurements meet the criterion. Activity values are checked in the order of Ki, IC50, Kd, and EC50. The first entry that meets the above activity threshold is used to determine "Standard Type", "Standard Relation", and "PubChem Standard Value". Otherwise, the first non-empty entry will be used to set those values.
Standard TypePubChem Standard ValueIC50Target Accession(s)LigandTarget
IC500.018318.3P08238BDBM20807Heat shock protein HSP 90-beta
IC505050000P08238BDBM50234650Heat shock protein HSP 90-beta
IC505050000P08238BDBM50303915Heat shock protein HSP 90-beta
IC500.2200P08238BDBM50325671Heat shock protein HSP 90-beta
IC500.462462P08238BDBM81729Heat shock protein HSP 90-beta
IC500.0660P08238BDBM50347493Heat shock protein HSP 90-beta
IC504.34300P08238BDBM76094Heat shock protein HSP 90-beta
IC5041.941900P08238BDBM225711Heat shock protein HSP 90-beta
IC500.154154P08238BDBM225712Heat shock protein HSP 90-beta
IC506.146140P08238BDBM225769Heat shock protein HSP 90-beta
IC506.146140P08238BDBM225769Heat shock protein HSP 90-beta
IC509.649640P08238BDBM225769Heat shock protein HSP 90-beta
IC509.649640P08238BDBM225769Heat shock protein HSP 90-beta
IC506.146140P08238BDBM225769Heat shock protein HSP 90-beta
IC506.146140P08238BDBM225769Heat shock protein HSP 90-beta
IC5055000P08238BDBM225777Heat shock protein HSP 90-beta
IC506.716710P08238BDBM225778Heat shock protein HSP 90-beta
IC500.096196.1P08238BDBM225782Heat shock protein HSP 90-beta
IC505050000P08238BDBM225831Heat shock protein HSP 90-beta
IC505050000P08238BDBM225836Heat shock protein HSP 90-beta
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL944268
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2009
Volume: 52
Issue: 4
First Page: 952
Last Page: 963
DOI: 10.1021/jm8008103
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
1000IC50>1000000nMOutside typical range
0.38IC50=380nM
192.6IC50=192600nMOutside typical range
53.7IC50=53700nM
4.9IC50=4900nM
0.5IC50=500nM
10.8IC50=10800nM
0.65IC50=650nM
0.14IC50=140nM
0.24IC50=240nM
0.13IC50=130nM
0.53IC50=530nM
1000IC50>1000000nMOutside typical range
5.2IC50=5200nM
0.28IC50=280nM
114.6IC50=114600nMOutside typical range
22IC50=22000nM
48.1IC50=48100nM
0.52IC50=520nM
0.32IC50=320nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: IGROV1_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, IGROV1 is panel number 6, cell number 10. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
0809OS51SM1.0E-5610Ovarian CancerIGROV1OVA89.6274101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA94.0185101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA77.1805101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA76.1686101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA82.5618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA88.7561101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA83.5845101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA92.7497101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA70.9555101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA58.7306101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.6041101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA90.3839101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA110.2345101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA97.6538101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA93.7697101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA56.4618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA80.8893101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA79.078101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA-20.3008101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.0949101
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL944270
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 2009
Volume: 52
Issue: 4
First Page: 952
Last Page: 963
DOI: 10.1021/jm8008103

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
0.04IC50=40nM
3.6IC50=3600nM
37.8IC50=37800nM
230.2IC50>230200nMOutside typical range
49.9IC50>49900nM
8IC50=8000nM
49.9IC50>49900nM
5IC50=5000nM
12.4IC50=12400nM
3.9IC50=3900nM
7.2IC50=7200nM
2.3IC50=2300nM
49.9IC50>49900nM
10.3IC50=10300nM
15.4IC50=15400nM
38.6IC50=38600nM
0.3IC50=300nM
29.2IC50=29200nM
3IC50=3000nM
41.2IC50>41200nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:24983 靶标:Huntingtin
External ID: KUHTS-Muma KU-CaM-Htt INH-01
Protocol: 1; Dispense 45 nl compounds (10 mM stocks) using ECHO 555 to Alpha 384 well assay plates. Dispense 45 nl DMSO to control columns 1 and 2 of 384 well plates.
2; Incubate 5 ul of 6XHis-mHTT (Final, 13 nM) with the compounds for 40 mins at room temperature in buffer containing 10 mM Tris.HCl pH 7.4, 1 mM calcium chloride, 150 mM sodium chloride, 0.1% BSA and 20% glycerol.
3; Dispense 5 ul of 6XGST-CaM (Final 13 nM) in buffer A.
4; Incubation; 1 hour (dark at 25C)
5; Dispense 20 ul of Nickel chelate acceptor beads (Final, 20 ugs/ml) and Glutathione donor beads (Final, 30 ugs/ml). Incubate for 2h, room temperature.
6; Detector: Perkin Elmer Enspire, Alphascreen Module (Excitation 680nm/Emission 570nm).

NOTES (numbers refer to Sequence numbers above)
1. Alphascreen bead incubations were performed in green light, TiterTek setting 400rpm.
2. All incubation and addition steps were followed by mixing and centrifugation at 400g,1 min.
3. The percent inhibition for each compound was calculated as follows:
100- [100 *((Test Compound-Median Low Control) / (Median High Control - Median Low Control))]

Where:
Test_Compound is defined as wells containing His mHTT + GST CaM in the presence of test compound

High_Control is defined as wells containing His mHTT + GST CaM and DMSO.

Low_Control is defined as wells containing His mHTT and DMSO.
Comment: All percent inhibition data reported were normalized to high and low controls on a per-plate basis. The results of primary screening data include compounds contributing to assay signal interference, interference with tags binding to Alpha beads, chelators, process related artifacts etc.. The actives were defined as compounds that inhibited Alphascreen reads to greater than 50%.
Activity at 15 uMPhenotype
-3.1
4.2
-4.8
-0.6
-3.9
-6
75.3Inhibitor
-10.3
-7
-2
-3.8
17.6
-4.8
-4.1
-7.8
-7.5
15.2
7.8
-2.5
-13.4